Clinical Trials Logo

Filter by:
NCT ID: NCT06026995 Recruiting - Lymphoma Clinical Trials

Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells

Start date: March 1, 2022
Phase: Phase 4
Study type: Interventional

This study is a randomized controlled, open and multi-center clinical study. Patients who meet the selection criteria and do not meet the exclusion criteria are randomly given PEG-rhG-CSF with a fixed dose of 12mg when white blood cells reach the lowest point, or given rhG-CSF with a daily mobilization of 5-10μ g/kg until the collection is completed, so as to evaluate the effectiveness and safety of PEG-rhG-CSF in mobilizing autologous stem cells for lymphoma and multiple myeloma.

NCT ID: NCT06026917 Recruiting - Clinical trials for Major Depressive Disorder

Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)

Start date: September 25, 2023
Phase: Phase 4
Study type: Interventional

This study was a single-arm, open-label clinical study to assess dopamine transporter occupancy in the brain of patients with depression using 11C-CFT positron emission tomography (PET).

NCT ID: NCT06026904 Recruiting - Intervention Clinical Trials

The Effects of taVNS on Motivation in MDD With Anhedonia

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

Study of non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) intervention to improve the reward motivation and response inhibition of major depression disorder and its brain network mechanism.

NCT ID: NCT06026891 Recruiting - Atopic Dermatitis Clinical Trials

Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis

Start date: January 13, 2024
Phase: Phase 3
Study type: Interventional

The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week

NCT ID: NCT06026878 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

GNT Induction Treatment in Locally Advanced NPC

Start date: September 1, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to compare overall response rate between gemcitabine, nimotuzumab and toripalimab as induction treatment and gemcitabine combined with cisplatine in paitents with locally advanced nasopharyngeal carcinoma. It aims to answer whether gemcitabine, nimotuzumab and toripalimab as induction treatment show non-inferiority compared to GP induction chemotherapy. Participants will be randomly divided into two induction treatment groups.

NCT ID: NCT06026839 Not yet recruiting - Acute Leukemia Clinical Trials

Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors

Start date: October 30, 2023
Phase:
Study type: Observational

Objective: To longitudinally track the dynamic changes in the survival quality of pediatric patients after hematopoietic stem cell transplantation at different time points within 1 year post-transplantation, analyze the influencing factors of survival quality at each time point, identify independent risk factors that can be intervened, provide reference for medical staff to recognize survival quality problems early, guide the dynamic management of clinical survival quality, and formulate continuation care management plans. Methods: This study adopted a repeated measurement study design. A total of 250 pediatric patients who underwent hematopoietic stem cell transplantation in three tertiary hospitals in Guangdong Province from August 2023 to December 2025 and met the research standards were selected as the research subjects. The "Childhood Health Assessment Questionnaire Transplant Module 3.0 Chinese Version" was used to evaluate the survival quality of the patients at six time points: 1 week before pre-treatment (T0), the day of stem cell infusion (T1), 1 month (T2), 3 months (T3), 6 months (T4), and 1 year (T5) after transplantation. Statistical methods for repeated measures were used to analyze the relevant information, and mixed-effect linear models were used to analyze the influencing factors of survival quality at the six time points, and to identify independent risk factors.

NCT ID: NCT06026826 Recruiting - Clinical trials for Magnetic Resonance Imaging

Intervention Effect of Transcranial Alternating Current Stimulation(tACS) on Anxiety Disorder

Start date: November 1, 2022
Phase: N/A
Study type: Interventional

To investigate the intervention effect of transcranial alternating current stimulation(tACS) on anxiety symptoms and somatic symptoms in patients with anxiety disorder and its underlying neural mechanism by MRI.

NCT ID: NCT06026800 Recruiting - Clinical trials for Digestive System Neoplasms

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Combination With Standard First-line Treatment in Subjects With Advanced Digestive System Neoplasms

Start date: September 8, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 in combination with first-line treatment in subjects with advanced digestive system neoplasms.

NCT ID: NCT06026774 Recruiting - Clinical trials for Digestive System Neoplasms

Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Subjects With Resected Digestive System Neoplasms

Start date: September 8, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, feasibility, and efficacy of personalized mRNA vaccine iNeo-Vac-R01 with standard adjuvant therapy in subjects with surgically resected digestive system neoplasms.

NCT ID: NCT06026748 Active, not recruiting - Clinical trials for Pneumococcal Disease

A Phase I Study of XJ103 in Chinese Healthy Subjects

Start date: September 12, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-parallel intervention clinical study that will include approximately 38 healthy subjects based on inclusion and exclusion criteria. Subjects will be assigned to one of four different dosage cohorts. Subjects in each cohort will randomly be given experimental drug or a placebo.